Search

Author/Creator Chan, Man

2. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Issue 9 (September 2022)

Authors:
Turkova, Anna; Waalewijn, Hylke; Chan, Man K; Bollen, Pauline D J; Bwakura-Dangarembizi, Mutsa F; Kekitiinwa, Adeodata R; Cotton, Mark F; Lugemwa, Abbas; Variava, Ebrahim; Ahimbisibwe, Grace Miriam; Srirompotong, Ussanee; Mumbiro, Vivian; Amuge, Pauline; Zuidewind, Peter; Ali, Shabinah; Kityo, Ci...
Journal:
Lancet
Issue:
Volume 9:Issue 9(2022)
Page Start:
e627
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Issue 9 (September 2022)

Authors:
Amuge, Pauline; Lugemwa, Abbas; Wynne, Ben; Mujuru, Hilda A; Violari, Avy; Kityo, Cissy M; Archary, Moherndran; Variava, Ebrahim; White, Ellen; Turner, Rebecca M; Shakeshaft, Clare; Ali, Shabinah; Nathoo, Kusum J; Atwine, Lorna; Liberty, Afaaf; Bbuye, Dickson; Kaudha, Elizabeth; Mngqibisa, Rosie;...
Journal:
Lancet
Issue:
Volume 9:Issue 9(2022)
Page Start:
e638
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗